학술논문

pH- and thermo-sensitive MTX-loaded magnetic nanocomposites: synthesis, characterization, and in vitro studies on A549 lung cancer cell and MR imaging
Document Type
article
Source
Drug Development and Industrial Pharmacy. 44(3)
Subject
Cancer
Biomedical Imaging
Nanotechnology
Bioengineering
A549 Cells
Acrylamides
Cell Line
Tumor
Drug Carriers
Drug Delivery Systems
Humans
Hydrogen-Ion Concentration
Lung Neoplasms
Magnetic Resonance Imaging
Methacrylates
Methotrexate
Nanocomposites
Nanoparticles
Polyethylene Glycols
Polymers
Silicon Dioxide
Theranostic nanomedicine
magnetic nanoparticles
dual-responsive drug delivery
lung cancer
methotrexate
MRI contrast agent
Pharmacology and Pharmaceutical Sciences
Language
Abstract
In the current study, we proposed a facile method for fabrication of multifunctional pH- and thermo-sensitive magnetic nanocomposites (MNCs) as a theranostic agent for using in targeted drug delivery and magnetic resonance imaging (MRI). To this end, we decorated Fe3O4 magnetic nanoparticles (MNPs) with N,N-dimethylaminoethyl methacrylate (DMAEMA) and N-isopropylacrylamide (NIPAAm), best known for their pH- and thermo-sensitive properties, respectively. We also conjugated mesoporous silica nanoparticles (MSNs) to polymer matrix acting as drug container to enhance the drug encapsulation efficacy. Methotroxate (MTX) as a model drug was successfully loaded in MNCs (M-MNCs) via surface adsorption onto MSNs and electrostatic interaction between drug and carrier. The pH- and temperature-triggered release of MTX was concluded through the evaluation of in vitro release at both physiological and simulated tumor tissue conditions. Based on in vitro cytotoxicity assay results, M-MNCs significantly revealed higher antitumor activity compared to free MTX. In vitro MR susceptibility experiment showed that M-MNCs relatively possessed high transverse relaxivity (r2) of about 0.15 mM-1·ms-1 and a linear relationship between the transverse relaxation rate (R2) and the Fe concentration in the M-MNCs was also demonstrated. Therefore, the designed MNCs can potentially become smart drug carrier, while they also can be promising MRI negative contrast agent.